News

Fast track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate

In this multi-center, dose escalating study, 80 patients will receive either RG2417 or a placebo for six weeks. Patients will be evaluated for the safety and effectiveness of

The company has completed patient enrollment in its first monotherapy trial and has now started this second trial to evaluate the oral entry inhibitor SP01A in what company

The 45 patient phase II trial met its primary endpoint of response to Algrx 4975 in treating pain induced by wrist dorsiflexion (bending back). Participants were given either

GSK’s development of the vaccine is slightly behind that of Merck & Co., which submitted Gardasil, its own cervical cancer vaccine, for approval in Europe and the US

The double-blind, randomized, dose-escalating study of peramivir is being conducted in association with the National Institutes of Health (NIH). The trial is being conducted at the NIH Clinical

The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it. In addition, the patent protects other similar antibodies also

The study’s principal investigator, Dr Ralph Hoffman, received a $2.1 million, five-year grant from the National Institute of Mental Health to expand the university’s research and recruit 90

The enzastaurin glioblastoma phase III trial is a randomized, open label registration study in recurrent glioblastoma multiforme (GBM), which will compare the efficacy, safety and tolerability of enzastaurin,